Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test

Psychopharmacology

Volumn 233, Issue 21-22, 2016, Pages 3763-3770

  Refsgaard, Louise K ^a   Haubro, Kia ^a   Pickering, Darryl S ^a   Stuart, Sarah A ^b   Robinson, Emma S J ^b   Andreasen, Jesper T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Affective bias; Antidepressant; Cognition; Depression; Emotional processing

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DULOXETINE; IDAZOXAN; SERTRALINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ACUTE DRUG ADMINISTRATION; ADULT; AFFECTIVE BIAS; AFFECTIVE BIAS TEST; ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; COGNITIVE BIAS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMOTION; EXPERIMENTAL BEHAVIORAL TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECALL; REWARD; SPRAGUE DAWLEY RAT; AFFECT; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DULOXETINE HYDROCHLORIDE; IDAZOXAN; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SULFIDES;

EID: 84984604083     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4407-6     Document Type: Article

References (56)

1. Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S (2009) Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 107:206–212
2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15:589–600
3. Arnone D, Horder J, Cowen P, Harmer C (2009) Early effects of mirtazapine on emotional processing. Psychopharmacology 203:685–691
4. Beck AT (1967) Depression: clinical, experimental, and theoretical aspects. Harper & Row, New York
5. Bolden-Watson C, Richelson E (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023–1029
6. Boulenger JP, Loft H, Florea I (2012) A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 26:1408–1416
7. Cassano GB, Puca F, Scapicchio PL, Trabucchi M (2002) Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. The Journal of Clinical Psychiatry 63:396
8. Chan SW, Goodwin GM, Harmer CJ (2007) Highly neurotic never-depressed students have negative biases in information processing. Psychol Med 37:1281–1291
9. Cipriani A, Koesters M, Furukawa TA, Nosé M, Purgato M, Omori IM, Trespidi C, Barbui C (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 10:CD006533
10. Cottingham C, Wang Q (2012) Alpha2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy. Neurosci Biobehav Rev 36:2214–2225
11. Culang-Reinlieb ME, Sneed JR, Keilp JG, Roose SP (2012) Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry 27:777–784
12. Disner SG, Beevers CG, Haigh EA, Beck AT (2011) Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12:467–477
13. Engleman EA, Perry KW, Mayle DA, Wong DT (1995) Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 12:287–295
14. Ferguson JM, Wesnes KA, Schwartz GE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18
15. Fontana DJ, Daniels SE, Henderson C, Eglen RM, Wong EH (1995) Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology 120:409–417
16. Gallassi R, Di Sarro R, Morreale A, Amore M (2006) Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 91:243–250
17. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1997) Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69:2616–2619
18. Gotlib IH, Krasnoperova E, Yue DN, Joormann J (2004) Attentional biases for negative interpersonal stimuli in clinical depression. J Abnorm Psychol 113:121–135
19. Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH (2014) Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat 2014:627863
20. Grossman E, Rea RF, Hoffman A, Goldstein DS (1991) Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Phys 260:R142–R147
21. Grossman F, Potter WZ, Brown EA, Maislin G (1999) A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 56:237–243
22. Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ (2013) Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 73:147–159
23. Gur RC, Erwin RJ, Gur RE, Zwil AS, Heimberg C, Kraemer HC (1992) Facial emotion discrimination: II. Behavioral findings in depression. Psychiatry Res 42:241–251
24. Halbreich, Montgomery (2005) Pharmacotherapy for mood, anxiety, and cognitive disorders. American Psychiatric Press, Inc.
25. Hales CA, Stuart SA, Anderson MH, Robinson ESJ (2014) Modelling cognitive affective biases in major depressive disorder using rodents. Br J Pharmacol 171:4524–4538
26. Harmer CJ (2013) Emotional processing and antidepressant action. Curr Top Behav Neurosci 14:209–222
27. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM (2003a) Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28:148–152
28. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM (2003b) Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 160:990–992
29. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. AJP 161:1256–1263
30. Harmer CJ, Heinzen J, O'Sullivan U, Ayres RA, Cowen PJ (2008) Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology 199:495–502
31. Harmer CJ, Goodwin GM, Cowen PJ (2009a) Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195:102–108
32. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, Goodwin GM, Cowen PJ (2009b) Effect of acute antidepressant administration on negative affective bias in depressed patients. AJP 166:1178–1184
33. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guárdia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 43:855
34. Horiguchi M, Huang M, Meltzer HY (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605–614
35. Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, Taiji M (2011) The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 220:83–90
36. Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215–223
37. Lewis CJ, Havler ME, Humphrey MJ, Lloyd-Jones JG, Mccleavy MA, Muir NC, Waltham K (1988) The pharmacokinetics and metabolism of idazoxan in the rat. Xenobiotica 18:519
38. Llorca PM, Lanon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C (2014) Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Current Medical Research & Opinion 30(12):2589–2606
39. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS (2015) A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40:2025–2037
40. Meneses A (2004) Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res 155:275–282
41. Millan MJ, Lejeune F, Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114–138
42. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340:666–675
43. Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C (2013) Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 105:41–50
44. Murai N, Fushiki H, Honda S, Murakami Y, Iwashita A, Irie M, Tamura S, Nagakura Y, Aoki T (2015) Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats. Neuroscience 289:262–269
45. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ (2009) Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 194:535–540
46. Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD, Reynolds CF III (2003) Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 37:99–108
47. Osman OT, Rudorfer MV, Potter WZ (1989) Idazoxan: a selective alpha-2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 46:958–959
48. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909
49. Shestyuk AY, Deldin PJ, Brand JE, Deveney CM (2005) Reduced sustained brain activity during processing of positive emotional stimuli in major depression. Biol Psychiatry 57:1089–1096
50. Sloan DM, Bradley MM, Dimoulas E, Lang PJ (2002) Looking at facial expressions: dysphoria and facial EMG. Biol Psychol 60:79–90
51. Stuart SA, Butler P, Munafo MR, Nutt DJ, Robinson ES (2013) A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology 38:1625–1635
52. Stuart SA, Butler P, Munafo MR, Nutt DJ, Robinson ES (2015) Distinct neuropsychological mechanisms may explain delayed- versus rapid-onset antidepressant efficacy. Neuropsychopharmacology 40:2165–2174
53. Tremaine LM, Welch WM, Ronfeld RA (1989) Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 17:542–550
54. van Veldhuizen MJA, Feenstra MGP, Heinsbroek RPW, Boer GJ (1993) In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br J Pharmacol 109:655–660
55. Walter DS, Flockhart IR, Haynes MJ, Howlett DR, Lane AC, Burton R, Johnson J, Dettmar PW (1984) Effects of idazoxan on catecholamine systems in rat brain. Biochem Pharmacol 33:2553–2557
56. Weikop P, Kehr J, Scheel-Kruger J (2004) The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol 18:395–403